Pfizer Inc.

The Beneish M-Score for 2025-FY is -2.522, which is below the -1.78 threshold and is labeled not in the elevated zone. In plain English, the model compares several year-over-year ratios, including receivables, gross margin, asset quality, depreciation, sales growth, and accruals, and a reading in this range does not carry the elevated manipulation-risk flag the model is designed to raise. It is a screening output rather than an audit conclusion, and it does not confirm that the reported figures are accurate. The second quality measure, operating cash flow divided by net income, is 1.51 for 2025-FY, meaning operating cash flow of $11.7 billion ran above net income of $7.77 billion. Cash generation exceeding earnings is generally a reassuring sign, but the ratio is lower than the 2024 level implied by the provided figures: $12.74 billion of operating cash flow against $8.03 billion of net income, a ratio of about 1.59. Revenue declined 1.7% to $62.58 billion in 2025, and the longer picture is steeper, with 2022 revenue at $91.79 billion. This synthesis is limited because no MD&A text, no risk-factor text, and no FACT-classified news headlines were on file. The filing's own explanations for the revenue decline, the debt increase, or any specific product, segment, legal matter, or regulatory issue therefore cannot be checked here. Readers may want to look at the MD&A and risk-factor sections of the company's annual report directly, particularly how management describes the drivers of revenue and the reasons for the rise in long-term debt. Those sections would supply the context that the numbers in this data set cannot.

Catalyst.No MD&A text was on file, so this paragraph relies only on reported results and cannot describe management's explanation of what is driving the business. On the reported figures, 2025 revenue was $62.58 billion, down 1.7% from $63.63 billion in 2024. Net income was $7.77 billion versus $8.03 billion, and operating cash flow was $11.7 billion versus $12.74 billion. The multi-year direction is also relevant: revenue was $91.79 billion in 2022 and $50.91 billion in 2023, so the top line has moved substantially from year to year. Net income was $2.12 billion in 2023 and $31.37 billion in 2022, and the 2025 figure sits between those levels.

Hidden risk.The most material item a casual reader could miss is long-term debt rising while equity shrinks. Long-term debt increased from $57.41 billion at the end of 2024 to $61.64 billion at the end of 2025, an increase of about $4.23 billion. Equity declined from $88.2 billion to $86.48 billion over the same period, which puts long-term debt at about 0.71 times equity (61.64 divided by 86.48). Operating cash flow fell from $12.74 billion to $11.7 billion, so the cash available to support that debt declined as the debt rose. Total liabilities did fall, to $121.39 billion from $124.9 billion, so the balance sheet is not weakening on every line. Without risk-factor text on file, the reason for the debt increase cannot be determined from this data.